• Life Sciences Companies Face Special Disclosure Challenges
  • March 10, 2006
  • Law Firm: Fenwick & West LLP - San Francisco Office
  • Life sciences companies face difficult disclosure issues because they operate in a particularly complex and financially sensitive regulatory environment. Given the necessary time and financial commitments, new product development is mission critical to the life sciences company. Naturally, this also creates keen investor incentives to track closely the progress of products in a company's pipeline through each stage of clinical development.